Aceptar todas las «cookies» garantizará que puedas disfrutar de la mejor experiencia en nuestro sitio web, incluyendo la personalización del contenido y las funciones para redes sociales. Aceptar únicamente las «cookies» necesarias permitirá un uso mínimo de «cookies» mientras navegas, pero es posible que algunas partes del sitio web no se muestren correctamente. Para saber más, consulta nuestra política de privacidad.
Amplexor in European Biopharmaceutical Review
by Romuald Braun, VP of Strategy at Amplexor
With regulatory compliance growing, we should expect to see data management transformation rising. However, this is not the case. Instead, we see companies throwing good money after bad money as they opt to invest in digitizing a process or updating an existing IT system. While, encouragingly, in 2019 organisations now appear to recognize the need for a more holistic approach, Life Sciences companies will need to focus attention on developing a vision for delivering this and mapping it to a hard strategy. Read the full article and learn more about why it's important for Life Sciences companies to move from approaching each project in isolation, to viewing them as part of a bigger vision.
This article is taken from European Biopharmaceutical Review January 2019, pages 86-87. © Samedan Ltd.